Phase 1 HER2-positive Clinical Trials
29 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–20 of 29 trials
Recruiting
Phase 1
Monitoring HER2+ Breast Cancer Neoadjuvant Treatment With Advanced PET/MRI
HER2-positive Breast Cancer
University of Alabama at Birmingham25 enrolled1 locationNCT04332588
Recruiting
Phase 1
Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic Breast Carcinoma+13 more
National Cancer Institute (NCI)36 enrolled2 locationsNCT07137416
Recruiting
Phase 1Phase 2
Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor
HER2-Positive Solid Tumor
Yuhan Corporation147 enrolled19 locationsNCT05523947
Recruiting
Phase 1
A Phase 1/1b Study of IAM1363 in HER2 Cancers
HER2-positive Breast CancerHER2 + Breast CancerHER2 Mutation-Related Tumors+10 more
Iambic Therapeutics, Inc383 enrolled53 locationsNCT06253871
Recruiting
Phase 1Phase 2
Dual-Target CLDN18.2/HER2 CAR-NK Cells for Advanced Esophageal Adenocarcinoma
Recurrent or Metastatic Esophageal AdenocarcinomaBiomarker-selected CLDN18.2-positive and/or HER2-positive Disease
Beijing Biotech36 enrolled1 locationNCT07622940
Recruiting
Phase 1
HER2 Vaccine for Locally Advanced Breast Cancer
Breast CancerHER2-positive Breast Cancer
Pravin T.P Kaumaya36 enrolled1 locationNCT06949410
Recruiting
Phase 1
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic Breast Carcinoma+37 more
National Cancer Institute (NCI)51 enrolled23 locationsNCT04704661
Recruiting
Phase 1
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Metastatic Breast CancerAdvanced Breast CancerMetastatic Lung Cancer+8 more
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)392 enrolled36 locationsNCT06625775
Recruiting
Phase 1Phase 2
A Study of BL-M07D1 in Patients With a Variety of Solid Tumors Including Locally Advanced or Metastatic HER2-positive/Low-expressing Urinary and Gastrointestinal Tumors
Her2-positive/Low-expression Urinary and Digestive Tract Tumors
Sichuan Baili Pharmaceutical Co., Ltd.42 enrolled1 locationNCT06031584
Recruiting
Phase 1Phase 2
Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC
Triple-Negative Breast CancerHER2-positive Breast CancerBreast Cancer (Advanced/Metastatic)
Beijing Biotech60 enrolled1 locationNCT07510802
Recruiting
Phase 1
A First in Human Dose Escalation of Dendritic Cell Vaccine (DCV)
Triple-Negative Breast CancerHER2-positive Breast CancerLeptomeningeal Disease
H. Lee Moffitt Cancer Center and Research Institute18 enrolled3 locationsNCT05809752
Recruiting
Phase 1
Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer
HER2-positive Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute28 enrolled1 locationNCT05378464
Recruiting
Phase 1
PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer
Triple-Negative Breast CancerMetastatic Breast CancerHER2-positive Breast Cancer+3 more
Royal Marsden NHS Foundation Trust45 enrolled9 locationsNCT04360941
Recruiting
Phase 1Phase 2
Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC)
HER2-positive Breast CancerTriple Negative Breast Cancer(TNBC)Breast Cancer (Locally Advanced or Metastatic)
Beijing Biotech60 enrolled1 locationNCT07486089
Recruiting
Phase 1Phase 2
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Breast CancerTriple-Negative Breast CancerColorectal, Cancer+26 more
PMV Pharmaceuticals, Inc300 enrolled76 locationsNCT04585750
Recruiting
Phase 1Phase 2
Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease
HER2-positive Breast CancerLeptomeningeal DiseaseLeptomeningeal Metastasis
H. Lee Moffitt Cancer Center and Research Institute39 enrolled2 locationsNCT04588545
Recruiting
Phase 1Phase 2
A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
HER2-positive Advanced Solid Tumor
DualityBio Inc.796 enrolled102 locationsNCT05150691
Recruiting
Phase 1Phase 2
Fruquintinib Combined With Trastuzumab and XELOX as First-line Treatment in Patients With HER2-positive Advanced Gastric Cancer
Gastric (Stomach) CancerGastric AdenocarcinomaGEJ Adenocarcinoma+3 more
Henan Cancer Hospital45 enrolled1 locationNCT07334431
Recruiting
Phase 1
A Study of VRN101099 in Patients With HER2-Positive Solid Tumors
HER2-Positive Solid Tumors
Voronoi, Inc72 enrolled1 locationNCT06806982
Recruiting
Phase 1
HER-2 B Cell Peptide Vaccine
Metastatic Breast CancerHER2-positive Breast CancerMetastatic Gastrointestinal Carcinoma+2 more
Pravin T.P Kaumaya42 enrolled1 locationNCT06414733